Life sciences span a wide range of disciplines that study living organisms in six categories, from molecules and cells to ecosystems and human health. The category that intersects in our world is Applied Life Sciences. And more specifically these fields that translate biological knowledge into practical solutions.
- Biotechnology – using living systems for technology and innovation
- Pharmacology – drug action and development
- Biomedical Science – disease mechanisms, diagnostics, therapeutics
- Stem Cell Biology & Regenerative Medicine – cell-based therapies
In this monthly report you will find news and highlights in the Applied Life Science.
Biotechnology
Orphan Therapeutics Accelerator Expands its Network to Extend Development and Access Pathways for Ultra-Rare Disease Therapies
Orphan Therapeutics Accelerator (OTXL), a non-profit biotech focused on completing development and enabling commercial access to shelved rare disease treatments, announced the expansion of its development network, Orphan ClinDevNet, through the addition of four strategic partners: OPIS, Uniphar, SK pharmteco, and TMC Pharma.
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
Clearmind Medicine Inc., a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, announced that it has been egranted an additional U.S. Patent, No. 12,357,590, titled “BINGE BEHAVIOR REGULATORS”, by the United States Patent and Trademark Office (USPTO).
Telum Therapeutics Secures €18 Million Series A Financing to Advance Lead Antimicrobial Program into Clinical Development
Telum Therapeutics, a biotechnology company leveraging proprietary metagenomic datasets, synthetic biology and generative AI to develop novel antimicrobial therapies, announced the successful completion of an €18 million Series A financing to advance its lead program targeting hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii.
Icosagen completes €45 million expansion, bringing therapeutic protein discovery, development and GMP manufacturing together under one roof
Estonia-based biotechnology company Icosagen has completed a major strategic expansion to strengthen its integrated biologics development and manufacturing capabilities at a single site, creating a seamless pathway from early discovery through GMP manufacturing for clinical supply of complex protein therapeutics.
Neurizon Executes Long-Term Supply Agreement with Elanco Strengthening Commercialisation Readiness
Neurizon® Therapeutics Limited, a late-stage clinical biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that it has executed a critical strategic supply agreement with Elanco Animal Health (“Elanco”) securing long-term access to human health monepantel, the active pharmaceutical ingredient in lead asset, NUZ-001. Importantly, the agreement provides Neurizon with access to scalable Good Manufacturing Practise (GMP) supply.
Pharmacology
BioMed X Launches Innovation Circle at BIO International Convention 2026
BioMed X, a build-to-solve innovation engine for pharma, officially launched the BioMed X Innovation Circle during the BIO International Convention 2026 last week, bringing together leaders from across the global life sciences ecosystem for an evening of meaningful dialogue, new connections, and cross-silo exchange.
Ryvu Therapeutics Presents Clinical Data and Program Update on Romaciclib at the European Hematology Association Congress 2026
Ryvu Therapeutics, a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, presents romaciclib (RVU120) data at the European Hematology Association Congress (EHA), June 11-14, 2026, in Stockholm, Sweden.
Stem Cell Biology & Regenerative Medicine
ModeX COVID-19 Antibody Enters Phase I Developed on ProBioGen’s Transposase Technology
ProBioGen congratulates its partner ModeX Therapeutics Inc., an OPKO Health company, on the successful advancement of its antibody candidate MDX2301 into Phase I clinical development. MDX2301 is a tetravalent antibody designed for the prevention of COVID-19 and aims to provide broad protection against diverse SARS-CoV-2 variants, particularly for individuals at increased risk of severe disease. ProBioGen supported this milestone by developing the production cell line for MDX2301, applying its proven producer cell line CHO.RiGHT® to enable efficient manufacturing of this complex antibody format.
MedTech and Medical Devices
Intermountain Health Doctors Perform 100th Surgical Procedure to Improve Lives of Epilepsy Patients Using High-Tech Brain Implants to Reduce Seizures
Intermountain Health neurologists are celebrating a major milestone: the 100th surgery of a groundbreaking implantable device that is proving to be a major success in reducing seizures in patients with patients with focal epilepsy.
Single Use Support Launches Next-Generation Controlled-Rate Blast Freezer
Single Use Support announces the release of its next generation RoSS.BLST, engineered to provide highly consistent freeze-thaw performance for biologics. The upgraded system enables CDMOs and biopharmaceutical manufacturers to strengthen product protection, improve process reproducibility, and increase overall operational efficiency.
BIOTRONIK Announces First U.S. Implant of Investigational Next-Generation Leadless Pacemaker
BIOTRONIK, a global leader in cardiovascular medical technology, announced the first U.S. implant of its LivIQ leadless pacemaker as part of the BIO-LivIQ global pivotal clinical trial. This next-generation single-device solution is developed to deliver atrioventricular (AV) synchrony through advanced electrical atrial far-field sensing. The implant was successfully performed by James Ip, MD, FACC, FHRS, Professor of Medicine, Director of Cardiac Pacing and Implantable Devices and Principal Investigator at Weill Cornell Medicine and a Cardiac Electrophysiologist at NewYork-Presbyterian/Weill Cornell Medical Center.
Clinical Studies and Trials
HEALEY ALS Platform Trial Surpasses 50% Dosing Milestone Ahead of Schedule
Neurizon Therapeutics said as of June 9, 167 participants had been assigned to Regimen I, with 129 receiving treatment across 78 active clinical trial sites in the US. The study represents Neurizon’s registrational trial for its lead drug candidate NUZ-001 in amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND).
T-CURX Non-Viral Siglec-6 Lead CAR-T Program, TCX-001, Was Approved for First-In-Human Phase 1 Clinical Trial in Patients with Relapsed/Refractory AML and CLL
Leading European CAR-T biotech company T-CURX announces its first clinical trial approval by Swiss agency Swissmedic for the company’s non-viral lead CAR-T program, TCX-001, targeting Siglec-6. The first-in-human Phase 1 study will now be initiated at University Hospital Zürich as the first clinical trial site to treat patients with relapsed/refractory (r/r) Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL), including patients that are not eligible for stem cell transplantation. A complementary CTIS application will also be filed at European Medicines Agency (EMA) to extend the trial to four sites in Germany led by University Hospital Würzburg (UKW). The study will enrol up to 23 adult patients with r/r AML or CLL to determine the recommended Phase 2 dose. Primary endpoints are safety, tolerability, and dose-limiting toxicities with key secondary endpoints including overall response rate, duration of response, as well as CAR-T cell expansion and persistence.
Mergers & Acquisitions Outlook
Source from PwC, Pharmaceutical and life sciences: US Deals 2026 midyear outlook
Biopharma and Biotech
Deal volume and value: Q1 2026 biopharma deal value >$65B, the strongest quarter since 2020, with 16 $1B+ deals announced.
Strategic drivers:
- LOE cliffs: Big pharma racing to offset an estimated $300B+ of branded revenue at risk this decade, using M&A to refill late‑stage pipelines.
- Therapeutic focus: Cardiometabolic (including GLP‑1), immunology, oncology, radiopharmaceuticals, vaccines, rare neurology, and genetic medicine are hot spots.
- Deal shape: Preference for mid‑cap biotech and bolt‑on platform acquisitions rather than mega‑mergers; many private‑company takeouts and specialty‑pharma scale plays.
AI and geography:
- AI‑enabled R&D is now a core deal consideration, both as an investment thesis and as a synergy lever in acquired pipelines.
- US and European buyers are increasingly tapping China-originated innovative molecules in oncology, immunology, and metabolic disease, adding geopolitical complexity to deal structures.
Medtech
Momentum: Medtech M&A stayed active through H1 2026, following a decade‑high 2025, with disclosed values supported by several scaled transactions.
Focus areas:
- Higher‑growth categories: Cardiovascular, neurostimulation, and ecosystem platforms (connected devices, monitoring, workflow).
- Portfolio reshaping: Carve‑outs, take‑privates, and divestitures as strategics refine focus and PE pursues operational value creation.
Market conditions: Capital‑market pressure and lower equity valuations are catalysts rather than brakes, pushing both strategics and sponsors toward assets with durable growth and defensible positions.
Events
ADLM Clinical Lab Expo (formerly AACC)
When: July 26-30, 2026
Where: Anaheim, CA
Event Page
Register for this event.
ADLM, which is the leading association for laboratory professionals, holds an annual clinical lab expo to discuss the latest science and prepare for what’s next in the field. Attendees have the opportunity to connect with leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of laboratory medicine. These connections and information sharing is done through lectures, plenary sessions, scientific sessions, and roundtable sessions.
Future BioTech Expo
When: August 19-20, 2026
Where: Houston TX
Event Page
Hashtag: #FBE26
Register for this event.
The Future Biotech Expo is the United States’ dedicated international exhibition and conference for red biotechnology, the science at the intersection of biology and human health. From pharmaceutical innovation and gene therapy to AI driven drug discovery and regenerative medicine, red biotech is rewriting what’s possible in healthcare. #FBE26 exists to accelerate that progress. Held in Houston, Texas, home to the world’s largest medical complex and one of the fastest-growing life sciences ecosystems in the US, Future BioTech Expo brings together the people, ideas, and capital that move the sector forward.
HLTH USA
When: November 15-18, 2026
Where: Las Vegas, NV
Event Page
Register for this event.
HLTH USA brings together professionals from pharma, tech, AI, health systems, and more to showcase healthcare and wellness innovation and how it may transform health. This year’s event will focus on ROI and accelerating goals. The overall goal of the conference is to bring together the healthcare ecosystem while creating “micro-experiences” tailored to participants.
